Simões Júlia Leão Batista, Braga Geórgia de Carvalho, Fontana Michelli, Assmann Charles Elias, Bagatini Margarete Dulce
Medical School, Federal University of Fronteira Sul, Chapecó 89815-899, SC, Brazil.
Department of Biochemistry and Molecular Biology, Federal University of Santa Maria, Santa Maria 97105-900, RS, Brazil.
Brain Sci. 2024 Dec 21;14(12):1286. doi: 10.3390/brainsci14121286.
Glioblastoma (GBM) is a highly lethal type of cancer, frequently presenting an unfavorable prognosis. The current treatment options for this neoplasia are still limited, highlighting the need for further research evaluating new drugs to treat GBM or to serve as an adjuvant to improve the efficiency of currently used therapies. In this sense, the inhibition of A2A receptors in the brain has presented a neuroprotective role for several diseases, such as neurodegenerative conditions, and it has been suggested as a possible pharmacological target in some types of cancer; thus, it also can be underscored as a potential target in GBM. Recently, Istradefylline (IST) was approved by the FDA for treating Parkinson's disease, representing a safe drug that acts through the inhibition of the A2A receptor, and it has also been suggested as an antineoplastic drug. Therefore, this work aims to explore the effects of A2A receptor inhibition as a therapy for GBM and assess the feasibility of this blockage occurring through the effects of IST.
胶质母细胞瘤（GBM）是一种高度致命的癌症类型，预后通常不佳。目前针对这种肿瘤的治疗选择仍然有限，这凸显了进一步开展研究以评估治疗GBM的新药或作为辅助药物提高当前所用疗法疗效的必要性。从这个意义上讲，抑制大脑中的A2A受体已对多种疾病（如神经退行性疾病）发挥了神经保护作用，并且在某些类型的癌症中被认为是一种可能的药理学靶点；因此，它也可被视为GBM的潜在靶点。最近，异他林（IST）已获美国食品药品监督管理局（FDA）批准用于治疗帕金森病，它是一种通过抑制A2A受体发挥作用的安全药物，也被认为是一种抗肿瘤药物。因此，本研究旨在探讨抑制A2A受体作为GBM治疗方法的效果，并评估通过IST的作用实现这种阻断的可行性。
